GlassScriptPhysician profile
Tammy Aftanas
NPI 1588069561
$2,304.63
in general payments reported to CMS, 2019-2025
21 companies · $532 in 2025
The $532 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $226 · 2022: $624 · 2023: $391 · 2024: $532 · 2025: $532.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,446 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,446.35 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $620.43 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $302.79 | 2022-2025 | Mavyret |
| Janssen Pharmaceuticals, INC | $265.20 | 2022 | |
| Xeris Pharmaceuticals, INC. | $229.08 | 2024-2025 | Gvoke Hypopen |
| Glaxosmithkline, LLC. | $207.01 | 2022-2025 | Arexvy, Shingrix, Bexsero |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $129.61 | 2023-2025 | Caplyta |
| Pfizer INC. | $94.86 | 2021-2025 | |
| Lilly USA, LLC | $89.71 | 2021-2025 | Mounjaro |
| Merck Sharp & Dohme LLC | $57.55 | 2021-2025 | Gardasil 9, Capvaxive |
| Corcept Therapeutics | $35.13 | 2025 | Korlym |
| Edwards Lifesciences Corporation | $33.48 | 2023 | |
| Amgen INC. | $32.19 | 2023 | Repatha, Otezla |
| Hologic Sales and Service, LLC | $29.46 | 2023 | Aptima, Thinprep 2000 Processor |
| Astrazeneca Pharmaceuticals LP | $28.05 | 2025 | Farxiga, Brilinta |
| Exact Sciences Corporation | $26.73 | 2023 | Cologuard Collection Kit |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $22.02 | 2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $21.30 | 2024 | |
| Jazz Pharmaceuticals INC. | $20.94 | 2021 | |
| Vbi Vaccine (Delaware) INC. | $20.69 | 2022 | |
| Axsome Therapeutics, INC. | $20.51 | 2025 | Auvelity |
| Phadia US INC. | $17.89 | 2024 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tammy Aftanas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.